Following the breakdown of the collaboration with JNJ, Geron (GERN) is finally ready to restart imetelstat's development. The Investigational New Drug ("IND") sponsorship transfer is now complete and the phase 3 trial for imetelstat in lower risk myelodysplastic syndrome ("MDS") is going to begin enrolling patients soon. While GERN's science continues to impress, management risks are piling up. To begin, we will look at imetelstat's status in MDS and myelofibrosis ("MF"), followed by a more holistic corporate overview.
Update on imetelstat in MDS
Imetelstat's clinical efficacy is continuing to impress. By way of